Radiation Oncology department
The Radiation Oncology Department at the Clínica Universidad de Navarra has extensive experience in administering modulated intensity external radiotherapy. We also use a wide variety of the latest medical-surgical techniques which are only available in very few Spanish centres.
The Clínica is an international reference centre for intraoperative implants and postoperative radiation treatments with high dose rate brachytherapy. We are one of the most experienced centres in the world for intraoperative brachytherapy treatment for head and neck tumours, soft structure sarcomas and gynaecological tumours.
We use stereotactic radiotherapy, which allows us to administer a number of very precise treatment sessions for oncological conditions.
We have a highly specialised nursing team who offer comprehensive patient care, focussing on working alongside other departments, controlling the disease and follow-up treatment for the symptoms and secondary effects associated with these conditions.
Furthermore, we carry out a lot of research work. Our Radiation Oncology Department has the larger number of publications in Spain.
We use the latest available medical-surgical techniques, which are only available in very few centres.
The technology available in the department, among others, is the following:
- Linear Accelerators (4): Elekta Versa HD (1), Siemens Mevatron Primus (2), Siemens Oncor (1)
- Multi-leaf collimator system (2) and Micromultileaf (1)
- Planning using CT/dedicated CT/fusion CT/MRI/PET scans
- High dose rate brachytherapy with Gammamed/Varian systems
- Very low dose rate brachytherapy with Semillas Oncura 125I
- CT scan room which can be converted into an operating theatre to carry out immediate, post implant CT scans
- Personalised planning for External Radiotherapy (ADAC), Modulated Intensity (ADAC/Konrad), Radiosurgery (Brainlab)
- High dose rate brachytherapy (Varian)
- Very low dose rate brachytherapy (Theratronics/Nucletron)
Estudio sobre la eficacia y seguridad del anticuerpo anti-pd-l1 en cáncer urotelial de vejiga tras fallo a quimioterapia basada en platino
El objetivo de este estudio es evaluar la eficacia y seguridad de MPDL3280A (anticuerpo anti-pd-l1) comparado con la quimioterapia en pacientes con cáncer vesical urotelial (CVU) localmente avanzado o metastásico, que experimentan progresión de la enfermedad durante o después de una pauta basada en platino.
Radiotherapy and Oncology Oct 13, 201